Journal of Nephrology & Renal Therapy Category: Clinical Type: Review Article

Advances in Residual Renal Function

Mengying Ji1,2, Liang Ren1 and Houyong Dai1*

1 Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, China
2 Medical School of Nantong University, Nantong, 226001, China

*Corresponding Author(s):
Houyong Dai
Department Of Nephrology, Affiliated Hospital Of Nantong University, Nantong, China
Email:daihy520@126.com

Received Date: Dec 09, 2024
Accepted Date: Dec 19, 2024
Published Date: Dec 26, 2024

Abstract

Residual Renal Function (RRF) refers to the filtration, reabsorption and endocrine functions of the preserved nephron after renal tissue damage. RRF plays an important role in solute clearance, electrolyte fluid balance, calcium and phosphorus control, inflammation and anemia. In this review, the importance of RRF, the influencing factors of RRF, how to calculate and evaluate RRF effectively and the protective measures of RRF are summarized, aiming at drawing attention to the protection of RRF and providing theoretical basis for clinical treatment and decision-making.

Keywords

Hemodialysis; Importance; Influencing Factors; Protection; Residual Renal Function

Introduction

Chronic Kidney Disease (CKD) has been recognized as a major global public health problem, and the global prevalence of CKD is estimated to be about 13.4% (11.7-15.1%) [1]. The latest epidemiologic survey shows that the prevalence of CKD in the Chinese adult population is 8.2% [2]. When CKD progresses to the stage of end-stage renal disease (ESRD), patients need to Take Renal Replacement Therapy (RRT), which includes Hemodialysis (HD), Peritoneal Dialysis (PD), and kidney transplantation. In the United States, HD accounts for 93% to 98% of first-time renal replacement therapy modalities for ESRD patients over 65 years old, PD accounts for 2% to 5%, and kidney transplantation is <2% [3]. Long-term Maintenance Hemodialysis (MHD) results in a progressive loss of Residual Renal Function (RRF) in ESRD patients. RRF is commonly overlooked in HD patients compared to peritoneal dialysis. Growing evidence shows that higher levels of RRF in HD patients are associated with better outcomes, such as improved quality of survival, solute clearance, nutrition, anemia, and phosphate control [4]. This review summarizes the research progress on RRF, aiming to draw attention to the protection of RRF and provide a theoretical basis for clinical treatment and decision-making.

Definition Of RRF

RRF is the filtration, reabsorption, and endocrine function of surviving renal units after damage to renal tissue. There is no uniform definition of RRF, which varies from study to study. A study by Singhal MK et al [5] defined loss of RRF as urine output <100 ml/d or creatinine clearance <1.0 mL/min. And in another study [6], it was defined as urine output <200 ml/d. RRF helps to achieve adequate solute clearance and is closely related to the health and survival of CKD patients. In addition, RRF maintains fluid balance and regulates electrolyte balance, reducing inflammation, anemia, and renal bone disease.

Importance of RRF 

  • RRF and risk of death 

When ESRD patients undergoing HD, a substantial RRF is present. Whereas, with the increase of dialysis vintage, RRF gradually decrease due to different cause. However, it can still be maintained at a low level, and once RRF is completely lost, dialysis efficacy is greatly reduced and the risk of death increases [7,8]. An analysis of the Netherlands cooperative study on the adequacy of dialysis (NECOSAD), which followed 740 HD patients, showed that per 1/week higher renal urea Kt/V the risk of mortality was reduced by 56% over a median follow-up of 1.7 years [9]. Importantly, RRF, even when maintained at low levels, reduces mortality in HD patients [10]. Thus, the presence of residual renal clearance is an important predictor of survival in HD patients. 

RRF and clearance of solutes 

HD provides interstitial solute clearance, whereas natural renal function is continuous, which may explain the benefit of RRF in patients with ESRD.RRF not only enhances clearance of small molecule solutes, but also plays an important role in the clearance of intermediate molecules and protein-bound uremic toxins, which are difficult to remove by HD. In a study involving 297 patients, beta-2 micro globulin (B2M) was used as a representative intermediate molecule and it was found that RRF was associated with better clearance of B2M [11]. 

RRF and fluid balance 

RRF plays an important role in the maintenance of fluid balance in dialysis patients, and the degree of removal of sodium and water is an important determinant of survival in dialysis patients [12]. RRF may be affected by changes in intravascular volume, and the occurrence of acute hypotension and volume depletion is responsible for a more rapid decline in RRF in HD patients [13-14]. 

RRF and inflammation 

A microinflammatory state exists in 35% to 65% of patients on hemodialysis [15], which are associated with platelet contact activation and complement cascade activation. Blood flow through the extracorporeal circuit leads to the release of a range of pro-inflammatory cytokines. In addition, decreased RRF is also an important factor causing a microinflammatory status [16]. In the CHOICE study, The levels of C-reactive protein and interleukin-6 were lower in patients with urine output (UO) >250 ml per day [17,18]. 

RRF and nutritional status 

RRF has a significant impact on the overall nutritional status of dialysis patients, which can be assessed by subjective overall assessment, grip strength or lean body mass [12]. The degree of RRF also affects micronutrient intake, including water- and fat-soluble vitamins and minerals [19]. In a retrospective study, RRF was shown to be associated with better nutritional status [20]. The involvement of native kidneys in protein metabolism may underlie the observation that patients on chronic HD who have RRF have better nutritional status [17]. 

RRF and renal anemia 

During the course of CKD, since the remnant nephrons are able to produce some amount of Erythropoietin (EPO), so RRF contributes to ameliorate renal anemia by improving the efficacy of EPO therapy and reducing EPO dosage. The CHOICE study showed that EPO requirements were reduced in hemodialysis patients with baseline urine output more than 250ml per day, and this was particularly notable in patients with preserved urinary output in one year after incident hemodialysis [18]. 

RRF, calcium and phosphorus metabolism 

Abnormal calcium and phosphorus metabolism is a common complication in MHD patients [21], which contributes largely to vascular and valvular calcification. Vascular calcification leads to a higher risk of death among HD patients [22], whereas heart valve calcification predicts overall mortality and cardiovascular disease mortality in patients undergoing peritoneal dialysis [23]. The results of a Latin American study in MHD patients [24,25] showed that too high or too low blood phosphorus and calcium concentrations increased all-cause mortality in HD patients. Some studies have confirmed a significant contribution of RRF to phosphate homeostasis, furthermore, the upregulation of FGF-23 may be a compensatory response that promotes phosphate excretion in MHD patients with RRF [26]. 

RRF and cardiovascular disease 

It is well known that cardiovascular disease is the leading cause of death in patients with MHD, and important determinants include accelerated atherosclerosis and Left Ventricular Hypertrophy (LVH). It has been demonstrated [25] that decreased RRF in HD patients is a risk factor for LVH, while the progressive loss of RRF leads to endovascular calcification and triggers adverse cardiovascular events. 

Assessment and calculation of RRF 

Renal function assessment in CKD patients mainly refers to Glomerular Filtration Rate (GFR) measurement, and there are 2 ways to assess GFR, namely, measured GFR (mGFR), which is assessed by the level of exogenous biomarkers, and estimated GFR (eGFR), which is assessed by the level of endogenous biomarkers. Inulin has long been the gold standard for mGFR, but is not widely used in clinical practice because of the complexity of the method. Radionuclides such as iodophthalate, 99mTc-DTPA, and 51Cr-EDTA have also been used for GFR determination [26,27]. Currently, 99mTc-DTPA renal dynamic imaging is often used clinically to measure GFR, which allows calculation of renal blood flow and assessment of single kidney function. Endogenous filtration markers such as serum creatinine (Scr) and urea nitrogen have been widely used to assess renal function. However, these methods have more or less drawbacks and limitations when assessing RRF in dialysis patients. 

In HD patients, there is no practical and validated method to assess RRF, and many factors in dialysis can affect its accuracy. Ideal markers for measuring GFR need to have the hallmark characteristics of constant production, free filtration, no metabolism, and not secreted or reabsorbed by the renal tubules [28]. For HD patients, the addition of inability to be cleared by dialysis is also needed. Therefore, small molecule solutes with high dialysis clearance, such as Scr and urea, would be inappropriate for RRF assessment. The assessment of RRF in dialysis patients is generally done by collecting 24-hour urine to determine their creatinine or urea concentration and calculating it. The KDOQI guidelines recommend the use of the mean value of urea nitrogen clearance and creatinine clearance in HD patients as an indicator for evaluating RRF [29]. In addition to the need to collect all urine from patients in the inter-dialysis period, this method also requires the collection of blood samples at multiple time points due to the huge fluctuations in serum concentrations of urea nitrogen and creatinine caused by dialysis clearance. These make the clinical operation very difficult and make it difficult to be widely used in the clinic. The simplest method to measure RRF is urine volume, which, despite its shortcomings, has been correlated with GFR in studies. Most authors define loss of RRF as a urine volume of <200 mL/d [6], and patients with RRF may undergo urine collection at baseline and every 1 to 3 months (PD for 24 hours and HD for the inter-dialysis period). Moreover, in a separate prospective cohort study, it was showed that higher residual urine volume was significantly associated with a lower risk of death and exhibited a stronger association with mortality than GFR calculated using 24-hour urine collection and eGFR-urea, creatinine, suggesting that determining residual urine volume may be useful and additive to predict prognosis in patients on dialysis compared with the other RRF indices [27]. 

The difficulty in obtaining reliable urine collection during the inter-dialysis period has prompted the search for new and improved methods. Proteins are gradually becoming a new direction in assessing RRF in dialysis patients due to their high molecular weight and low dialysis clearance. The molecules that have been the subject of more clinical studies include cystatin C (CysC), β2-Microglobulin (B2M) and β-Trace Protein (BTP). Cystatin C is a cysteine protease with a molecular weight of 13.3 kD, produced by all nucleated cells. It is freely filtered in the glomerulus and is almost entirely absorbed and catabolized by the proximal tubule [30]. Cystatin C increases with inflammation, hyperthyroid states, and may be affected by smoking, high doses of steroids, and triglycerides [31]. In contrast to Scr, the most important characteristic of Cystatin C is that it is produced continuously, independent of muscle mass, age, or gender, and is not secreted or absorbed. Because of its unique properties, it has been used as a marker of mild renal damage in most studies [32-34]. Disadvantages of Cystatin C include the higher cost of immunoassays and too much intra-individual variability to detect renal damage early. 

B2M is part of the major histocompatibility class I antigens with a molecular weight of 11.8 kD and is present on the cell surface of all nucleated cells [35]. B2M is freely filtered in the glomerulus and then enters the proximal tubule for catabolism and metabolism. With the exception of chronic kidney disease, elevated B2M is associated with inflammatory status, myeloma, age, and male gender [36]. B2M is cleared by high flux HD and hemofiltration [37]. Individual differences in B2M are evident, especially in patients with very weak renal function or no RRF. BTP is a glycoprotein with a molecular mass between 23-29 kD and has been used as a marker of cerebrospinal fluid leakage [38]. It accumulates in renal failure, and serum BTP levels correlate closely with residual urine volume in hemodialysis. BTP cannot be removed by conventional low or high-flux dialysis. Although hemodiafiltration removes some BTP, [39] its levels are not significantly altered during the inter-dialysis period [40]. extra-renal elimination appears to be minimal [41]. Because of these properties, BTP is expected to serve as a marker of RRF in dialysis patients. 

In isolation, Cystatin C, B2M, and BTP do not meet the ideal criteria for endogenous markers of the GFR. Therefore, it has been suggested that more accurate prediction equations can be derived by combining the factors [34]. These prediction equations are considered preliminary and require extensive external experiments for validation.

Factors affecting residual renal function

Currently, the KDOQI guidelines identify several risk factors for RRF decline in CKD patients, such as age, race, blood pressure, and proteinuria [42,43]. It is indicated that the higher the ultrafiltration rate in HD patients, the faster the decline in RRF and the lower the survival rate [44]. The risk of RRF loss was reported to be 65% lower in patients treated with peritoneal dialysis than in patients treated with HD, which was attributed to better hemodynamic stability [45]. Obesity and high BMI are important risk factors for RRF decline after the initiation of dialysis treatment [46,47], and despite a more rapid decline in RRF, it is associated with better survival, at least in HD patients [13]. In addition, diabetes mellitus, congestive heart failure [48], and high ferritin levels [49] are important predictors of RRF loss. Some treatment-related factors such as hypotension on dialysis, biologically incompatible dialysis membranes, and frequent dialysis have been associated with rapid loss of RRF.

Protection of residual renal function

Drugs to protect RRF 

  • RAAS blockade 

The role of ACEIs and ARBs analogs in slowing CKD progression and reducing proteinuria in non-dialysis CKD patients is well known [50,51]. A meta-analysis by Ding et al [52] showed that the use of ACEIs or ARBs reduced the decline in RRF in patients on peritoneal dialysis. There are fewer studies on ACEIs and ARBs in HD patients. Xydakis et al [53] reported that enalapril was associated with better preservation of RRF in a 1-year study of 42 HD patients.

Diuretics

Opinions on the effect of diuretics on RRF are not yet uniform. Two studies involving patients with PD [54-55] showed that the use of diuretics independently predicted a more rapid decline in RRF. In contrast, in another study [56], results showed that patients treated with diuretics were twice as likely to have retained urine output at 1 year after the start of dialysis treatment. Chen et al [57] is conducting a randomized controlled trial in China to further evaluate the role of furosemide for prevention of intradialytic hypotension and its effect on RRF in HD patients.

Other drugs

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have been shown to slow the progression of chronic kidney disease [50], and therefore may provide protection against RRF among dialysis patients [58]. Recently, a case series of report indicated that the use of SGLT2i in DKD patients starting iHD on a 1–2 weekly regimen appears to be safe and effective in preserving RRF [59].

Blood Pressure Control

The relationship between RRF and blood pressure is complex, both hypotension and hypertension leading to an increased risk of RRF decline in dialysis patients [14]. The KDOQI guidelines currently recommend ACEIs or ARBs as the drug of choice for blood pressure control in patients with severe RRF deficiency [33]. Currently, there is no clear definition of the ideal blood pressure level for dialysis patients, and excessive blood pressure fluctuations as well as prolonged hypotension or hypertension should be avoided.

Incremental dialysis

Incremental dialysis has received increasing attention in recent years. Currently, the impact of incremental dialysis on RRF is unclear, and the results of studies vary. There is no clear signal of an overwhelming risk or benefit of twice-weekly HD compared with three times-weekly HD [32]. KDOQI and EBPG support the use of incremental HD prescriptions, provided that the RRF is monitored regularly to avoid inadequate dialysis.

Biocompatible dialysis membranes and ultrapure dialysate solutions

Repetitive exposure of blood to dialysis membranes during HD gives rise to inflammation that affect RRF adversely. Indeed, compared to HD patients treated with cellulose acetate membrane, those patients with the more biocompatible polysulfone membrane had a slower decline of RRF [47]. Ultrapure dialysate fluid combined with high-flux synthetic membranes is reported to slow the loss of RRF in HD patients [30]. Avoidance of radiographic contrast agents, nonsteroidal anti-inflammatory drugs, and aminoglycosides is an important consideration for RRF in MHD patients. The results of a meta-analysis showed that the use of contrast agents may not lead to a significant reduction in RRF in dialysis patients [28]. However, the long-term effects of radiographic contrast agents on RRF are minimized by using low-permeability contrast agents as much as possible in the clinic and by implementing an appropriate hydration regimen.

Low-protein diet

Of note, some research data suggest that adopting a low-protein diet (0.6-0.7 g/kg/d) in combination with incremental dialysis on non-dialysis days may be helpful for RRF preservation. The KDOQI guidelines recommend a protein intake of 1.2 g/kg/d for stable MHD patients, but in practice many patients have difficulty achieving the guideline-recommended level. Some studies have suggested that combining a low or very low protein diet with essential amino acids or ketones is beneficial in preserving RRF in dialysis patients while avoiding malnutrition and inflammation [7-8]. During hemodialysis, a routine to high protein diet can still be recommended considering the higher catabolic rate and loss of amino acids.

Conclusion

In conclusion, RRF has been shown to be important for the long-term survival of dialysis patients, mainly in terms of benefiting various aspects such as nutritional status, fluid balance, metabolism, and other aspects. Therefore, increased attention to and protection of RRF in HD patients, regular monitoring of RRF, and targeted preventive measures can lead to better protection of RRF in dialysis patients, resulting in improved quality of life and survival.

References

  1. Lv JC, Zhang LX (2019) Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol 1165: 3-15.
  2. Wang L, Xu X, Zhang M, Hu C, Zhang X, et al. (2023) Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Intern Med 183: 298-310.
  3. Tamura MK, Tan JC, O'Hare AM (2012) Optimizing renal replacement therapy in older adults: a framework for making individualized decisions. Kidney Int 82: 261-9.
  4. Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, et al. (2011) CONTRAST investigators. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 6: 281-9.
  5. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG (2000) Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 20: 429-38.
  6. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, et al. (2000) Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11: 556-564.
  7. Caria S, Cupisti A, Sau G, Bolasco P (2014) The incremental treatment of ESRD: A low-protein diet combined with weekly hemodialysis may be beneficial for selected patients. BMC Nephrol 15: 172. 
  8. Jiang N, Qian J, Sun W, Lin A, Cao L, et al. (2009) Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: A prospective, randomized trial. Nephrol Dial Transplant 24: 2551-8. 
  9. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, et al. (2004) NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15: 1061-70.
  10. Shemin D, Bostom AG, Laliberty P, Dworkin LD (2001) Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38: 85-90. 
  11. Fry AC, Singh DK, Chandna SM, Farrington K (2007) Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 25: 295-302.
  12. Wang AY, Lai KN (2006) The importance of residual renal function in dialysis patients. Kidney Int 69: 1726-32.
  13. Patel N, Hu SL (2015) Preserving residual renal function in dialysis: what we know. Semin Dial 28: 250-8.
  14. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, et al. (2002) NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 62: 1046-53.
  15. Menaa C, Esser E, Sprague SM (2008) Beta2-microglobulin stimulates osteoclast formation. Kidney Int 73: 1275-81.
  16. Francisco RC, Aloha M, Ramón PS (2013) Effects of high-efficiency postdilution online hemodiafiltration and high-flux hemodialysis on serum phosphorus and cardiac structure and function in patients with end-stage renal disease. Int Urol Nephrol 45: 1373-8.
  17. Suda T, Hiroshige K, Ohta T, Watanabe Y, Iwamoto M, et al. (2000) The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 15: 396-401.
  18. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, et al. (2010) Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 56: 348-58.
  19. Wang AY, Sea MM, Ip R, Law MC, Chow KM, et al. (2002) Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. Am J Clin Nutr 76: 569-76.
  20. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K (2009) Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 24: 2502-10.
  21. Taniguchi M (2010) [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality]. Clin Calcium 20: 1078-87.
  22. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-42.
  23. Wang AY, Wang M, Woo J, Lam CW, Li PK, et al. (2003) Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 14: 159-68.
  24. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, et al. (2011) Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 26: 1938-47.
  25. Chen HC, Chou CY, Jheng JS, Chen IR, Liang CC, et al. (2016) Loss of Residual Renal Function is Associated With Vascular Calcification in Hemodialysis Patients. Ther Apher Dial 20: 27-30.
  26. Wang M, You L, Li H, Lin Y, Zhang Z et al. (2013) Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function. Clin J Am Soc Nephrol 8: 116-25.
  27. Lee MJ, Park JT, Park KS, Kwon YE, Oh HJ, et al. (2017) Prognostic Value of Residual Urine Volume, GFR by 24-hour Urine Collection, and eGFR in Patients Receiving Dialysis. Clin J Am Soc Nephrol 12: 426-434.
  28. Oloko A, Talreja H, Davis A, McCormick B, Clark E, et al. (2020) Does Iodinated Contrast Affect Residual Renal Function in Dialysis Patients? A Systematic Review and Meta-Analysis. Nephron 144: 176-184.
  29. National Kidney Foundation (2015) KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis 66: 884-930.
  30. Schiffl H, Lang SM, Fischer R (2002) Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17: 1814-8.
  31. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, et al. (2005) Cystatin C as a marker of GFR--history, indications, and future research. Clin Biochem 38: 1-8.
  32. Moorman D, Pilkey NG, Goss CJ, Holden RM, Welihinda H, et al. (2022) Twice versus thrice weekly hemodialysis: A systematic review. Hemodial Int 26: 461-479.
  33. Hemodialysis Adequacy Work Group (2006) Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48 Suppl 1:S2-90.
  34. Inker LA, Couture SJ, Tighiouart H, Abraham AG, Beck GJ, et al. (2021) CKD-EPI GFR Collaborators. A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population. Am J Kidney Dis 77: 673-683.e1.
  35. Revillard JP, Vincent C (1988) Structure and metabolism of beta-2-microglobulin. Contrib Nephrol 62: 44-53.
  36. Stanga Z, Nock S, Medina-Escobar P, Nydegger UE, Risch M, et al. (2013) Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level. PLoS One 8: e72073.
  37. Pickett TM, Cruickshank A, Greenwood RN, Taube D, Davenport A, et al. (2002) Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purif 20: 161-6.
  38. Hochwald GM, Pepe AJ, Thorbecke GJ (1967) Trace proteins in biological fluids. IV. Physicochemical properties and sites of formation of gamma-trace and beta-trace proteins. Proc Soc Exp Biol Med 124: 961-6.
  39. Gerhardt T, Pöge U, Stoffel-Wagner B, Klein B, Klehr HU, et al. (2008) Serum levels of beta-trace protein and its association to diuresis in haemodialysis patients. Nephrol Dial Transplant 23: 309-14.
  40. Shafi T, Michels WM, Levey AS, Inker LA, Dekker FW, et al. (2016) Estimating residual kidney function in dialysis patients without urine collection. Kidney Int 89: 1099-1110.
  41. Olsson JE, Link H, Nosslin B (1973) Metabolic studies on 125I-labelled beta-trace protein, with special reference to synthesis within the central nervous system. J Neurochem 21: 1153-9.
  42. Iwasawa H, Nakao T, Matsumoto H, Okada T, Nagaoka Y, et al. (2013) Phosphate handling by end-stage kidneys and benefits of residual renal function on phosphate removal in patients on haemodialysis. Nephrology (Carlton) 18: 285-91.
  43. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al. (2003) National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-47.
  44. Lee YJ, Okuda Y, Sy J, Lee YK, Obi Y, et al. (2020) Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis. Am J Kidney Dis 75: 342-350.
  45. Shahab I, Khanna R, Nolph KD (2006) Peritoneal dialysis or hemodialysis? A dilemma for the nephrologist. Adv Perit Dial 22: 180-5.
  46. Drechsler C, de Mutsert R, Grootendorst DC, Boeschoten EW, Krediet RT (2009) le Cessie S, Wanner C, Dekker FW, NECOSAD Study Group. Association of body mass index with decline in residual kidney function after initiation of dialysis. Am J Kidney Dis 53: 1014-23.
  47. Hartmann J, Fricke H, Schiffl H (1997) Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 30: 366-73.
  48. Lowenstein J, Grantham JJ (2017) Residual renal function: a paradigm shift. Kidney Int 91: 561-565.
  49. Hur SM, Ju HY, Park MY, Choi SJ, Kim JK, et al. (2014) Ferritin as a predictor of decline in residual renal function in peritoneal dialysis patients. Korean J Intern Med 29: 489-97.
  50. Patel SM, Kang YM, Im K, Neuen BL, Anker SD, et al. (2024) Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation 149: 1789-1801.
  51. Li T, Wilcox CS, Lipkowitz MS, Gordon-Cappitelli J, Dragoi S (2019) Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients. Am J Nephrol 50: 411-421.
  52. Ding L, Yang J, Li L, Yang Y (2020) Effects of ACEIs and ARBs on the Residual Renal Function in Peritoneal Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int 6762029.
  53. Xydakis D, Papadogiannakis A, Sfakianaki M, Kostakis K, Stylianou K, et al. (2013) Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation. ISRN Nephrol 2012:184527.
  54. Szeto CC, Kwan BC, Chow KM, Chung S, Yu V, et al. (2015) Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 35: 180-188.
  55. Liao CT, Shiao CC, Huang JW, Hung KY, Chuang HF (2008) Predictors of faster decline of residual renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int S191-S195.  
  56. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, et al. (2007) Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49: 426-431.
  57. Chen W, Wang F, Zhao Y, Zhang L, Chen Z, et al. (2021) Efficacy and safety of furosemide for prevention of intradialytic hypotension in haemodialysis patients: protocol for a multicentre randomised controlled trial. BMJ Open 11: e048015.
  58. Heerspink HJL, Berger S, Gansevoort RT (2023) Renal Life Cycle Trial Investigators. Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation. Clin J Am Soc Nephrol 18: 1500-1502.
  59. De La Flor JC, Villa D, Cruzado L, Apaza J, Valga F, et al. (2023) Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? Biomedicines 11: 1908.

Citation: Ji M, Ren L and Dai H (2024) Advances in Residual Renal Function. J Nephrol Renal Ther 10: 096.

Copyright: © 2024  Mengying Ji, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Science. Our mission is to provide an access to knowledge globally.



© 2025, Copyrights Herald Scholarly Open Access. All Rights Reserved!